Primary care providers are no doubt familiar with SGLT2 inhibitors from extensive experience with T2DM; however, SGLT2 inhibitors are now indicated to treat CKD in patients with and without T2DM.9, 10, 11. This evidence concerns the gene SLC5A2 and chronic kidney disease.